Compare FISV & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FISV | INSM |
|---|---|---|
| Founded | 1984 | 1988 |
| Country | United States | United States |
| Employees | 38000 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1B | 30.1B |
| IPO Year | N/A | 2000 |
| Metric | FISV | INSM |
|---|---|---|
| Price | $56.00 | $154.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 24 |
| Target Price | $146.17 | ★ $200.48 |
| AVG Volume (30 Days) | ★ 6.1M | 2.3M |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $177.03 |
| Revenue Next Year | $3.92 | $66.55 |
| P/E Ratio | $9.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $52.91 | $63.81 |
| 52 Week High | $70.41 | $212.75 |
| Indicator | FISV | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 43.87 | 51.40 |
| Support Level | $52.91 | $137.93 |
| Resistance Level | $68.35 | $167.01 |
| Average True Range (ATR) | 1.78 | 6.54 |
| MACD | 0.25 | 1.09 |
| Stochastic Oscillator | 55.18 | 59.43 |
Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Following its 2019 merger with First Data, Fiserv also provides payment processing services to merchants. About 10% of the company's revenue is generated internationally.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.